On January 19, 2023 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX:13) reported, following negotiations with the China National Healthcare Security Administration ("NHSA"), ORPATHYS (savolitinib) has been included in the updated National Reimbursement Drug List ("NRDL") for the treatment of locally advanced or metastatic non-small cell lung cancer ("NSCLC") adult patients with MET exon 14-skipping alterations who have progressed after or unable to tolerate platinum-based chemotherapy (Filing, 6-K, HUTCHMED, JAN 19, 2023, View Source [SID1234626387]). The updated NRDL will take effect from March 1, 2023.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Savolitinib, marketed in China under the brand name ORPATHYS, is an oral, potent and highly selective MET tyrosine kinase inhibitor ("TKI") jointly developed by AstraZeneca and HUTCHMED with HUTCHMED taking the lead in China, and commercialized by AstraZeneca worldwide.
Dr Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED, said: "The NRDL has significantly broadened access to novel medicines for Chinese patients. We are gratified to see that our third novel oncology medicine, ORPATHYS, will be included in this year’s NRDL update. As the first and only selective MET inhibitor in the market, the inclusion of ORPATHYS will increase the affordability and access to this novel treatment."
Leon Wang, Executive Vice President, International and China President of AstraZeneca, said: "The inclusion of ORPATHYS on the NRDL is exciting news for NSCLC patients in China with MET exon 14 skipping alterations who will now have improved access to the only targeted medicine approved in this setting and who often do not respond well to chemotherapy. Since its launch in mid-2021, ORPATHYS has helped patients in need achieve better outcomes, and we are excited about the potential to reach even more patients in China with this transformational medicine."
ORPATHYS received conditional approval in China in June 2021 for the treatment of certain patients with NSCLC with MET exon 14 skipping alterations